Editorially independent · We do not sell peptides

Hexarelin

Synthetic hexapeptide ghrelin-receptor agonist · GH-releasing + cardioactive

EVIDENCE GRADE
C
Limited
TYPE
Hormonal
EU
NOT AUTHORISED
US
NOT AUTHORISED
MOLECULAR INFORMATION

Molecular information

Length
10 amino acids
Type
Synthetic hexapeptide ghrelin-receptor agonist · GH-releasing + cardioactive
Amino acid sequence
His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH₂

Hexarelin is a synthetic hexapeptide GHRP, developed in Italy in the 1990s as a candidate for GH-deficiency states. Distinct from other GHRPs in its documented cardiovascular signalling (CD36-mediated), which has driven ongoing research interest in cardioprotection independent of GH release.

Claims vs evidence

  • GH release — comparable to other GHRPs
  • Cardioprotection — preclinical evidence; one small Phase 1 in heart failure
  • Tolerance / tachyphylaxis — well-documented; chronic dosing diminishes effect

Why we grade it C

Plausible mechanism with some cardiovascular evidence, but no authorised product and no adequately-powered Phase 3. The tolerance issue makes real-world therapeutic use difficult. Listed primarily because grey-market peptide vendors continue to stock it.

Related compounds

Other compounds in this category